We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.55% | 9.15 | 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | 1,054,095 | 12:15:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/2/2019 09:58 | The REALITY EFFECT - There is nothing like a 'New S P LOW' to bring-out the LIES and FALSE CLAIMS from the 'underwater trHYPERS / Swallowers'. Then, when they are shown to be telling LIES / making FALSE CLAIMS, for the 'underwater trHYPEERS/ Swallowers' to display their petulant bitterness towards the 'CORRECT'. The REALITY EFFECT { as explained above } is even more evident, when the 'CORRECT' point-out the likelyhood of a'pending' 'New LOWER share price LOW'. | the real lozan | |
13/2/2019 18:35 | Old timer.. you could have mowed the whole of France given the time you've wasted here over the years. Sad to watch, but the bully beats you over and over again. ATB :) | wigwammer | |
13/2/2019 18:32 | Loz, nothing wrong with Thailand per se. My brother lives there, hoping to go and visit sometime in the next year or two. | gazza | |
13/2/2019 17:54 | Tosh et al - Made all the better by knowing 'How FAR AWAY we are from Thailand' | the real lozan | |
13/2/2019 17:09 | Enjoy Lozan Nice life. | tosh123 | |
13/2/2019 16:16 | Flat man - You may have noticed, I had to terminate your education today... As I used my time - profitably...by Lawn Mowing {Maxed out at 27 C in the sun...24 C just now....I think a beer is deserved} | the real lozan | |
13/2/2019 14:51 | Brilliant..... the idiot has the audacity to accuse RR... " you cannot even forecast 4 hrs ". Coming from the bloke that has CONTINUALLY made NUMEROUS forecasts, that have been WRONG every time, and not just wrong by a penny, but wrong by thousands of percents, its absolutely priceless... i cant stop laughing. Doesn't he realise just how stupid he makes himself look... Classic comedy, from a witless clown. | tosh123 | |
13/2/2019 12:57 | Looks like market is catching up with the management message. Happy days :) "News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price." | wigwammer | |
13/2/2019 12:42 | To pick up on Ivy's comment. I see a platform spread of 63/67... that's from an earlier 6.1/6.1356 (or thereabouts) !!! See what you mean Ivy ATB | oldnotwise | |
13/2/2019 12:27 | Morning. What is with huge spread.Thought my 2 last buys at 6.2 and 6.8 was brave or foolish but it looks like more brave fools still about lol | ivyspivey | |
13/2/2019 12:03 | Bermuda >would be interesting to get NXC's opinion if he's around.<<br /> Yes, It certainly would having been involved in previous placings and discussions with iis. | gazza | |
13/2/2019 11:41 | Hmm. Quite clear to US ALL that the old timer is struggling to argue with the more important point. "News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price." I don't really enjoy conversing with you. Perhaps if the others share your interest, or strongly disagree with my £6.5m estimate, they can chat to you about it. ATB :) | wigwammer | |
13/2/2019 11:29 | Flatman - Care to explain to *US ALL* how you arrive at /would have *US ALL* believe a "cash position" circa £6.5 mil EXISTS ??? ACTUALLY EXISTS...NOW = mid FEB 2019 | the real lozan | |
13/2/2019 11:03 | Ah well, at least the old timer isn't arguing about the more important point. "News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price."Happy to let others decide whether circa £6.5m represents a decent cash position ex trial costs. | wigwammer | |
13/2/2019 11:03 | Now there's a thing... I see one of the newer posters on LSE having "cracked" Scancell's science is now writing a trading program. This is based simply on share price movements, AND IT WORKS!!!!! Well, that's an achievement. I wonder, since it takes nothing into consideration of Volumes what's going to happen the first time a significant "Stop" is hit in the market? Well, I suppose a mind that can master Scancell's science in a few months can certainly build a reliable "Trading System" in no time at all..... AND, "It Works"! Can't wait to watch SCLP's price movements when it's all up and running... Just think a home grown prog that can execute many trades a second and IT works!!! Profits all round!! AIMO ATB | oldnotwise | |
13/2/2019 10:52 | WRONG - "without trial costs, they have enough cash to get them through circa 18 months." . NO they HAVE NOT | the real lozan | |
13/2/2019 10:50 | Panama, i have read the article,which doesn't really tell us anything than we didnt already know... However, contrary to some IDIOTS continual drivel, a couple of things that it does PROVE, are ... " Scancell is working on two technologies that are showing early promise – eg ;- Early promise, yes thats right, early promise... NOT ITS PROVEN... and... " Modi-2 vaccine has the POTENTIAL to treat different types of cancer..... yes thats right, it has the POTENTIAL , NOT ITS PROVEN.. Right from the horses mouth... Hopefully having been proven to be totally WRONG on his understanding of CFD's, and now having been proven to be totally WRONG, by our own BOD on his " PROVEN " statement, he will now crawl away and leave the adults to debate on a balanced basis. | tosh123 | |
13/2/2019 10:46 | Bermuda - I agree - they will not aim to raise cash until after the trial news has progressed. I suspect the one line they wanted investors to take away from the proactive article yesterday was the following "News on the start of the Phase II clinical study of SCIB1 in combination with Keytruda could see it return to the £50mln valuation of the May 2018 placing price." In the meantime, without trial costs, they have enough cash to get them through circa 18 months. ATB :) | wigwammer | |
13/2/2019 10:37 | Tosh, maybe Calculus have already voiced their discontent, they no longer have a voice on the BOD, have not replaced Cornish-Bowden. Also Glencross had a telephone conversation with Holloway back in July/August and immediately posted on Twitter to all his followers that the combi trial was on track to start by end of year. I can't imagine finding out in a matter of weeks that the trial had been further delayed went down very well. | panama7 | |
13/2/2019 10:35 | Some interesting views this morning! I wonder how I'd react as a new investor. I look at the share price and charts, but what do I actually think? There must be many who'll look at the share price high and low, and think having seen the current level, OK must be worth a few shares at this price. Then there's anyone that can actually understand the Science who sadly might actually not be a regular investor in the stockmarket. He may like the science but doesn't buy the shares because? He doesn't "do" stockmarkets... Horses for courses. There may be some who do follow the market (and BBs) and those that do will find that as a generality BBs have been extremely optimistic for the company since (almost) Day One. What do these potential investors see? Possibly a PUNT on a bombed out share which is displayed as world beating:- top of the class, holds the keys to the kingdom, can't fail, etc etc etc... BUT, the potential investor has to say to himself, "Why's the share price where it is?" That might be our reason for being where we are. The new Investor's decisions are likely to determine where we go in the short term. My guess (in the absence of Outstanding Funding News or significant Data)is that there'll be a resurgence in the share price at some point, but if there is there'll be likely to be a significant and sizeable selling to block upward movement when the new "Investors" see sufficient profit to satisfy their short term targets. IF and it's a big if, the Bunny isn't part of that researgence, the BOD if they need cash will be forced to raise and that is likely to "Lid" the share price for some time.... THEN we wait until the DATA chain starts and then hopefully we can start to breathe freely again... I reckon we need either, BUNNIES DATA OXYGEN Hopefully in that order, but I'll accept anything really to get us into some sort of quantifiable stability! AIMO ATB | oldnotwise | |
13/2/2019 10:23 | Berm, i've been shocked that the II's haven't been more vocal ( maybe they have been at BOD level, we dont know ). Their investments have taken a hammering every year, and for any fund manager to be showing continuous year on year losses against the "same stock ", takes some justifying to his employers and investors. Even with the various discounted offerings, ALL of them will now be considerably out of the money, so to be able to justify a further cash injection will be difficult, if not impossible. Our only hope is the fluffy bunny rabbit IMHO. | tosh123 | |
13/2/2019 10:18 | Gazza, haven't a couple of the major II's been unable to support recent fundraisings due to their exposure to Scancell and the % rules of their investment, although I suppose with the share price at this level the % may have changed. With regards to Caoculus their % ownership of Scancell must have been reduced significantly since 2013 and the failed sale. | panama7 | |
13/2/2019 10:09 | Tosh, did you not see the action from the BOD yesterday in the article on Proactive Investors. A really pathetic attempt at supporting the share price Why oh why are we using Proactive, it has proved over years to be a total waste of time and space. The only people who see it are existing holders , their articles and presentations have never led to any interest in the stock. Why oh why if we have this great data keeping all these terminally ill patients alive are we not shouting it out in the main media, a total dereliction of duty by our BOD to protect the interests of their long suffering long term holders. | panama7 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions